Speeding the Delivery of CAR-T Therapies While Cutting the Cost

The Bio Report
|

Automatic TRANSCRIPT

Greg. Thanks for joining US getting so much standing. My pleasure. We're GONNA talk about Cartesian therapies, exuma biotech, and your efforts to develop rapid point of care delivery of these therapies. Let's start with Cartesian therapies themselves out of these therapies work today. Well you know if we were to look at this technology today. And put it in the context of what we do in science and medicine even fifteen years ago. The the thought that we could truly have living medicine with genetically modified. LYMPHOCYTES in the body would have been unheard of it. And really I think the basic process of taking one cells from the body. In reprogramming genetically lymphocytes in returning them back into a patient to retrain those cells to see cancer antigens much in the same way we've done with monoclonal antibodies in the past, but wiring all that into itself is what is made Carta. Medicine which has been both exciting in is of course had. Equally that the number of challenges in in many different areas. Well. How are these therapies typically prepared and administered? Well it's a complicated process that has. A tremendous amount of technical skill required as well as logistics so typically. When a subject is entering into a trial or on therapy for approved medicines, their blood is drawn and separated into white blood cells and then shipped usually on a plane to a central manufacturing facility where those cells then are taken into a cleanroom, they are activated their genetically modified they're grown for about. Fifteen days, and then they are prepared just like you would with drug. And then ship back to the site. So there's a tremendous amount of time that can be lost for patients during this period and then once those cells. Are received. Back The patient receives Olympic depleting chemotherapy regimen to kind of make space. And then the cells are infused and at that point they take off and they're on their own. These cell therapies have been more successful in hematological answers than in solid tumors. What why is that? Well I. Think if you look at the history of the Field Dang, what you will find is that. One of the principal challenges in building cellular therapies has been it. They can be incredibly potent. So in the case of something, we know very well like CD nineteen, this isn't a liquid tumor setting those cells with CD nineteen will eliminate. All targets in the body that express CD nineteen, and this is found in many lymphomas. leukaemias. But the problem is in the case of CD nineteen, you're eliminating all of the normal cells make CD nineteen, which are called E. Cells, and this is tolerable in the case of liquid tumors. But when you think about the antigens targets that we go after in solid tumors, those are often expressed in tissues that. Not Be safe if the immune system were to attack it. So we've been forced to really take steps back on how well we can make a car for solid tumors to try and make them smarter to help recognize friend from foe. So the great efficacy I think that you've seen in relapse refractory ael l.. As well as in diffuse large B. Cell Lymphoma, and now also I think exciting we in places like multiple myeloma getting that stain level of efficacy in solid tumors has required that people really think about the precision inside of the problem to make sure can get a potent car but also one that is safe.

Coming up next